Optimal design of a population pharmacodynamic experiment for ivabradine

Pharmaceutical Research

Volumn 18, Issue 1, 2001, Pages 83-89

  Duffull, S B ^a   Mentre F ^b   Aarons, L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Fisher information matrix; Ivabradine; Optimal design; Pharmacodynamics; Population analysis

Indexed keywords

CARDIAC AGENT; IVABRADINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG RESEARCH; METHODOLOGY; MODEL; PHARMACODYNAMICS; POPULATION RESEARCH; PRIORITY JOURNAL; PRODUCTIVITY; SAMPLING; STEADY STATE;

BENZAZEPINES; CARDIOTONIC AGENTS; CLINICAL TRIALS, PHASE I; HUMANS; SAMPLING STUDIES; TIME FACTORS;

EID: 0035049209     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011035028755     Document Type: Article

References (18)

1. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers
2. A pharmacokinetic simulation model for ivabradine
3. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers
4. Optimal design in random-effects regression models
5. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics
6. Design of cross-over trials for pharmacokinetic studies
7. Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients
8. Optimal multicompartmental sampling designs for parameter estimation: Practical aspects of the identification problem
9. Optimal sampling times for pharmacokinetic experiments
10. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments
11. Development and implementation of the population Fisher information matrix for evaluation of population pharmacokinetic designs
12. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria
13. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis
14. Design of experiments for estimating enzyme and pharmacokinetic parameters
15. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters